Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYDM68)

• Drug Name: BGP-15 Drug Info
• Synonyms: 66611-37-8; BGP-15 2HCl; 3-Pyridinecarboximidamide, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-, hydrochloride (1:2); BGP 15; BGP15; SCHEMBL3067994; MolPort-039-099-291; MolPort-027-834-918; s8370; AKOS016007888; AKOS026745444; SB17119; CS-6045; 3-Pyridinecarboximidamide, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-, dihydrochloride; BGP-15, > AS-16983; TC-162219; AX8217132; KB-258115; HY-100828; (Z)-N'-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidamide dihydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 9884807
  CAS Number: CAS 66611-37-8
  TTD Drug ID: DMYDM68

Molecule-Related Drug Atlas

Drug(s) Targeting Poly [ADP-ribose] polymerase (PARP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Olaparib	DM8QB1D	Ovarian cancer	2C73	Approved	[3]
Rucaparib	DM9PVX8	Ovarian cancer	2C73	Approved	[4]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[5]
MK-4827	DMLYGH4	Ovarian cancer	2C73	Phase 3	[6]
BSI-201	DMM0VO3	Solid tumour/cancer	2A00-2F9Z	Phase 3	[7]
Rubraca rucaparib	DM25TMP	Ovarian cancer	2C73	Phase 3	[8]
ABT-888	DM4HYMS	Breast cancer	2C60-2C65	Phase 3	[6]
INO-1001	DM5L8QT	Brain cancer	2A00	Phase 3	[9]
BGB-290	DMRO6XT	Ovarian cancer	2C73	Phase 2	[8]
2X-121	DMX9MSL	Breast cancer	2C60-2C65	Phase 2	[8]

Drug(s) Targeting Jun N terminal kinase (JNK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AM-111	DM4E9PK	Neurological disorder	6B60	Phase 3	[10]
CC-401	DMPMO6G	Solid tumour/cancer	2A00-2F9Z	Phase 2	[11]
CC-930	DMHVEGJ	Discoid lupus erythematosus	EB51.0	Phase 2	[12]
PMID25991433-Compound-Q1	DMEMSB2	N. A.	N. A.	Patented	[13]
PMID25991433-Compound-O1	DMH073T	N. A.	N. A.	Patented	[13]
2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One	DMDN12L	Discovery agent	N.A.	Investigative	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Jun N terminal kinase (JNK)	TTR2TXZ	MK08_HUMAN; MK09_HUMAN; MK10_HUMAN	Inhibitor	[2]
Poly [ADP-ribose] polymerase (PARP)	TTEBCY8	NOUNIPROTAC	Modulator	[1]

References

• [1] BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [5] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [6] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [7] Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012 Mar 15;18(6):1655-62.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock. 2010 May;33(5):507-12.
• [10] The JNK inhibitor XG-102 protects against TNBS-induced colitis.PLoS One.2012;7(3):e30985.
• [11] Signal integration by JNK and p38 MAPK pathways in cancer development.Nat Rev Cancer.2009 Aug;9(8):537-49.
• [12] In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism. Xenobiotica. 2015;45(6):465-80.
• [13] c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
• [14] c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001 Jul;108(1):73-81.